DCC-2701 Altiratinib VEGFR Inhibitors Cas 1345847-93-9
DCC-2701 Altiratinib VEGFR Inhibitors Cas 1345847-93-9
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:DCC-2701 Altiratinib |
Purity:99.0% min |
|
CAS NO:1345847-93-9 |
Solubility:DMSO33 mg/mL (64.65 mM) |
|
Molecular Formula:C26H21F3N4O4 |
Package:Package according to customer requirements |
|
Molecular Weight:510.465 |
Storage:Store at -20℃ |
Quality control
Remarks
Altiratinib, also known as DCC-270, DP-5164, is an oral, selective and highly potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases with potential anticancer activity. DCC-2701 effectively reduces tumor burden in vivo and blocks c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Importantly, DCC-2701's anti-proliferative activity was dependent on c-MET activation induced by stromal human fibroblasts and to a lesser extent exogenous HGF.
Related Prodcuts:
LY2874455; ZM-306416; ZM323881; Tyrphostin A9; Orantinib; Brivanib; Foretinib; SU5402; Semaxanib; SAR131675; Lucitanib; Apatinib; SKLB610; SGI-7079; AZD2932
References
[1].Smith BD, et al. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated DrugResistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015 Sep;14(9):2023-34.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.